The development of new medicines is one of the priority areas of translational medicine. A significant role for biomarkers (BM) that assess the safety and efficacy of new drugs. The right choice of BM reduces the time and costs necessary for the development of drugs and transfer them to the clinic. The review is devoted to the analysis of modern scientific literature on the role of previously known and newly discovered BM in translational research. Translational BM (TBM) established during preclinical studies and are applicable at all stages of the study. TBM should have a high sensitivity and specificity, be easily measured in real time in an easily accessible biological fluids, to evaluate the same process in different species of animals (including humans), make it possible to compare the results of clinical trials with preclinical. The main role of the TBM toxicity to predict, identify and monitor the toxicity of drugs at all stages of their study. The international consortium (Predictive Safety Testing Consortium, PSTC) whose main task is the qualification of new TBM toxicity and the search for new, more advanced than existing methods for testing markers, was established. Under PSTC formed 6 working groups, each of which coordinates research for the study and selection of TBM toxicity caused by the administration of drugs in the liver, kidney, heart and blood vessels, skeletal muscle, testes. The first qualified consortium markers were 7 contained in the urine markers for preclinical studies on rats with the goal of establishing early lesions in the kidney induced by drugs. Only a small number of BM used in the study of new drugs, can be translational.

Currently, mammography is the main screening method for diagnosing breast cancer (BC); but the process of carcinogenesis begins long before the appearance of a visualized tumor. For successful early diagnosis of breast cancer, a systematic approach is required, that includes all stages of tumor development. On the example of BC we consider the possibilities of integrating the recent scientific achievements of oncogenetics and proteomics with standard methods. In this article we investigate the possibilities of using genetic research, serum cancer markers and radiation methods for early diagnosis of BC. This article also presents potential options for managing high-risk development of this disease.

Breast cancer is the most common disease in women all over the world. In the structure of cancer morbidity, breast cancer ranks first and its frequency is steadily increasing. In the world, about 1.67 million new cases are diagnosed and every year more than 500,000 women die from breast cancer. Triple negative breast cancer (TNBC) is about 15–20 % of all breast tumors; is more common in women of fertile age. TNBC is characterized by a lack of expression of estrogen, progesterone receptors and HER-2/neu, which significantly complicates the treatment of this disease, which is characterized by aggressive course, the maximum risk of recurrence during the first 3 yearsafter surgical treatment, and rapid metastasis and decreased life expectancy. This article presents a review of the literature on the molecular-biological characteristics of TNBC. The article also describes the main approaches to targeted therapies for each subtype.

Up till now human papillomaviruses (HPV) draw attention of biologists and clinicians owing mostly to the fact that some members of this group cause cervical cancer in women. However it is clear that both women and men take part in HPV distribution throughout population. Data get accumulated on peculiarities of HPV natural history in men when compared with women, as well as on capability of oncogenic HPV to induce cancer in several male organs. The present paper is an attempt to synthesize literature data on specific features of HPV natural history in men. Elucidation of these features is important for working out efficient approaches for prevention of HPV-associated malformation with regard to gender specificities.

The appearance of modulators immune synapse in clinical practice has become a revolution in metastatic skin melanoma treatment. However, blockade PD-1 allows to achieve objective response in only 30–40 % of patients. Recently, many mechanisms of primary resistance of melanoma to immunotherapy studied, they related both to the characteristics of the tumor and the tumor microenvironment. The response to anti-PD-1 therapy usually is durable, but acquired resistance emerges in 25 % of patients, who had an objective response to this treatment. This review will describe the main mechanisms of resistance to anti-PD-1 therapy in metastatic skin melanoma and possible ways of their overcoming.

Cervical cancer (CC) in recent years has increased significantly. The main cause of death in patients with СС IIB–IV stages are the recurrence and metastasis of tumors, often with involvement of pelvic and lumbar lymph nodes. Ultrasound diagnosis is one of the leading places in modern oncology, because of such advantages as non-invasive, harmless method, the possibility of multiple studies, the availability and relatively low price of the study. Currently, ultrasound appears more new, additional methods aimed at improving the qualityand information content of the image. One of such methods is elastography, to assess the elasticity of tissue by assessing the hardness of the formation in real time non-invasive manner. Despite the fact that separate research points to advances in modern technology, there is no information under what situations their use is most informative, or impractical, due to existing limits of the method. In other words, there is a need for the formation of algorithm of using ultrasonic techniques to achieve optimum results when assessing the effectiveness of treatment of СС.

Introduction. There is ample evidence that disseminated tumor cells (DTC), which are found in the bone marrow (BM) of patients with breast cancer (BC), including early stages, are progenitors of subsequent distant metastasis. Therefore, BM-DTC represent an additional tool for understanding carcinogenesis and estimating prognosis. Nevertheless, the existing data are controversial. The purpose of the study – to determine the frequency of DTC detection in BM of patients with luminal BC and also its relationship with some clinical and immunophenotypic parameters. Materials and methods. BM bioptates of 65 luminal BC patients were analyzed for the presence of DTC by Attune Acoustic Focusing Cytometer. For the first time in Russia, the sensitivity of the DTC detection method in the BM to the level of 1 × 10–7 myelocaryocytes was increased. Results. In BM, DTC were detected in 40 % of patients, and this finding did not correlate with stage of BC and degree of malignancy. The level of CD8+ lymphocytes in patients with DTC in the BM was significantly lower and amounted to 39,2 % versus 48,1 % in patients without DTC (p = 0,011). The content of myelocaryocytes with DTC-positive status was 1,6 times lower than in the absence of DTC (р = 0,007). Other parameters of the myelogram did not differ significantly. Moreover, no significant correlations were found between the presence of DTC in BM and the breast tumor immunophenotype (HLA-I: p = 0,74; HLA-DR: p = 0,93; CD71: p = 0,46). Conclusion. The presence of BM-DTC is more interrelated with myelogram and subpopulation of BM lymphocytes than with the clinical characteristics of tumor.

Currently it is a constant search for new and effective methods of protection against ischemic injury in limb-salvage surgery on kidneys. Objective – improvement of functional results of surgical treatment, reducing the time of hospitalization. Materials and methods. We conducted a clinical trial involving 69 patients. Time “warm ischemia” – 14,2 ± 2,4 min. All performed on the kidney sparing surgery for renal cell carcinoma for elective indications. After surgery, the study group (n = 35) held sessions of hyperbaric oxygenation parallel receiving α-tocopherol acetate. The control group included 34 patients. The analysis of inflammatory changes in tindicators of total blood test, glomerular filtration rate, the state of immunity, peripheral circulation, renal function, the assessment of quality of life was performed. Results. The scheme of post-operative rehabilitation of patients with renal cell carcinoma helps to activate the anti-inflammatory and immune response to surgical treatment, more rapid and complete restoration of blood flow and function of organ operated. Conclusion. This reduces the incidence of postoperative complications and period of hospitalization.

Aranosa, nitrozourea derivative is a DNA-methylating agent that has been approved for treatment of patients with disseminated melanoma. Aranoza effect is based on DNA damage and then as a result apoptosis mechanisms start launching. The important role in this process must be played by p53 protein, and its different dysfunctions can result in drug resistance. Objective. The purpose is to study p53 mutational status in cell lines of human skin metastatic melanoma and to estimate its connection with сell lines resistance to aranoza. Materials and methods. The research was conducted on 14 cell lines of human skin metastatic melanoma. Aranoza IC50 for cell lines was determined by MTT-test. The 17р chromosome’s condition was estimated by fluorescence in situ hybridization. The presence of point mutations in DNA-binding domain of human p53 was researched by Sanger sequencing. Results. Skin metastatic melanoma cell lines had different sensitivity to aranoza. Almost all cell lines were heterogeneous in the condition of 17 th chromosome. P53 point mutations were found in 2 cell lines. But one part of resistant cell lines almost didn’t have any mutational disorders of p53, another part of resistant lines on the contrary had plenty of p53 mutational disorders. Conclusion. The correlation of resistance and p53 mutations can be established for one part of human skin metastatic melanoma cell lines. But for another part of human skin metastatic melanoma cell lines resistance most likely are driven by other mechanisms.

Fluorescent probes based on monoclonal antibodies (MAb) are widely used in scientific and clinical research in the field of oncology, hematology, immunology, epidemiology. Objective: to create of fluorescent probes based on the MAb and the fluorescent dye Alexa-488 for the analysis of cellular populations by flow cytometry. Materials and methods. MAb to B lymphocyte antigen (clone ICO-180), fluorescent dye Alexa-488 were used in the work. MAb was isolated from ascitic fluid by combined purification of the immunoglobulin fraction with caprylic acid and salting out with ammonium sulfate. Gel filtration on a PD-10 column was used to purify the conjugates (immunofluorescent probes, IFP), the concentration and labeling density of the IFP were determined spectrophotometrically. The determination of the working titer of the IFP was performed using the antibody titration method proposed by C.C. Stewart. Results. The optimal time of incubation of MAb with a fluorophore was experimentally determined. The optimal conditions for labeling MAb of the IСO series with the dye are: a carbonate buffer with pH 8,3, the concentration of antibodies in the reaction mixture is 1 mg/ml, molar ratio of active dye – 10–100 mmol per 1 mmol of protein, the incubation time is 90 minutes, the temperature is 18–25 °C. We obtained a panel of conjugates of MAb with Alexa-488, differing in their different labeling densities. Evaluation of the biological activity of the resulting conjugates was carried out on peripheral blood cells of donors in the concentration range of MAb 0,5–100 μg/ml. Conclusion. The optimal conditions for labeling MAb of the IСO series with the dye are: a carbonate buffer with pH 8,3, the concentration of antibodies in the reaction mixture is 1 mg/ml, the incubation time is 90 minutes, the temperature is 18–25 °C. The optimum density of labeling is in the range 5–13,5 M:M, the optimal concentration of antibodies is in the range of 5–25 μg/ml.

In accordance with Russian Federal program of import substitution of foreign medicines quality of Russian drugs in the N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, played vincristine-RONC (VC-RONC), which as a drug – the generic’s passed preclinical pharmacological and toxicological testing in comparison with foreign firms vincristine Teva of Israel (VC-Teva). The aim. The aim of present study was the comparative pathomorphological evaluation of the effect of VC-RONC and VC-Teva on the internal organs of rats. Materials and methods. Used 50 weinbrenner male rats, at 10 rats per group. VC-RONC and VC-Teva rats were administered intravenously 3 times daily at aquatoxicity total dose corresponding to the MTD and 1/2 MTD. Control rats in the same regime intravenously administered of 0,9 % sodium chloride solution. Rats were deduced from the experience of 3 and 30 days after the end of administration of the drugs. Conducted macroscopic and histological examination of internal organs by conventional methods, including fixation of the material in 10 % formalin and coloring sections with hematoxylin and eosin. The micropreparations of the internal organs was analyzed under light microscope at magnifications of 100, 400, 1000. Results. VC-RONC, as VC-Teva in cumulative doses of 0,5 and 0,25 mg/kg in 3 days after the end of introductions in the internal organs of rats cause similar slightly pronounced morphological changes: hypoplasia in the bone marrow and spleen, destructive changes in the testes, focal degenerative changes in the kidney and liver of individual rats. On the 30th day after the application of both drugs, some rats regardless of the dose occurred similar symptoms residual morphological changes in the bone marrow, testes, kidneys and liver. Conclusion. Based on the results of macroscopic and histological examination the conclusion about the similarity of the influence of VC-RONC and VC-Teva on the internal organs of rats was made.

The use of liposomes as drug delivery systems today is a recognized approach to improving the effectiveness of treatment. Compared with other nanosized carriers, liposomes are highly biocompatible. However, in the literature, there are a number of data on the immunogenicity of some liposomal drugs. Hypersensitivity reactions of moderate to severe severity were noted in some patients with intravenous administration of liposomes Doxil®, Ambisome®, DaunoХome®. The technology of production of liposomes is a laborious process and obtaining liposomal forms on an industrial scale is problematic for researchers and manufacturers around the world. In connection with this, studies on the scaling up of technology for obtaining liposomes and studying the specific toxicity of liposomal preparations are relevant. Objective – evaluation of the quality of prototypes of liposomal dosage form based on tetra-3-phenylthiophthalocyanine hydroxyaluminum obtained by scaled technology in comparison with samples produced in laboratory conditions, as well as studying their mutagenic and immunotoxic properties. Object of the study – tetra-3-phenylthiophthalocyanine hydroxyaluminum liposomal, lyophilizate for the preparation of injection for injection of 1,5 mg, in bottles with a capacity of 20 ml (LLF). Materials and methods. Bengem’s method, extrusion, sterilizing filtration, lyophilization, intercellular contact integrity test (for promoter activity), Ames bacterial test, cytogenetic study of chromosomal aberrations, DNA damage test (DNA comet test), Erne method; hypersensitivity reaction of delayed type, determination of mass and cellness of central and peripheral immunity organs, evaluation of phagocytic activity of peritoneal macrophages. Results. Based on the results of the research, the LLF production technology is scaled, which allows obtaining up to 400 LLF flasks per production cycle. It has been established that LLF at doses of 6 and 24 mg/kg does not cause an increase in the number of chromosomal abnormalities in mice and does not cause DNA damage, in doses of 1,1–22,0 μg/dish LLF does not show mutagenic activity in the Ames bacterial test, in the range concentrations of 0,062–3,1 μg in the test for promoter activity does not separate intercellular contacts. It is determined that in doses of 6 and 12 mg/kg, LLF does not affect humoral and cellular immunity, does not change the mass and cellularity of the central and peripheral organs of the immune system. LLF, 24 hours after administration at doses of 6 and 12 mg/kg, dose-dependently decreases the phagocytic activity of peritoneal macrophages, which is restored after 7 days. Conclusion. The technology of LLF production is scaled. In the doses studied, it was found that LLF does not have the ability to promote the process of carcinogenesis and the lack of influence on the humoral and cellular immune response.

The Her2 receptor is an important target for antitumor therapy in the treatment of breast cancer. Trastuzumab, based on anti-Her2 monoclonal antibodies, is used in clinical practice. Trastuzumab is produced by animal cells culture technology and is quite expensive. We use the technology of production of recombinant antibodies in the plants Nicotiana benthamiana with a high yield of final purified protein. Objective. The aim of following study is a comparison of monoclonal antibodies received via classic cell culture technology and produced in plant biomass. Materials and methods. Recombinant plant-made antibodies were isolated by affinity chromatography from the biomass of N. benthamiana plants agroinfiltrated by vector constructs. Comparison of affinity properties was carried out by immunocytochemical staining of cells and competitive binding using flow cytometry analysis. Results and conclusion. We show that the antibodies expressed in N. benthamiana are equal to those obtained from mammalian cells in binding to Her2 antigen localized on the surface of the SK-BR-3 cells. In the present work it was shown that the plant-made anti-Her2 antibodies do not differ in specific binding with the Her2 antigen, as well as with IV subdomain of the Her2 receptor.